Stockholders' Equity Attributable to Parent in USD of Vitro Biopharma, Inc. from Q3 2011 to Q2 2025

Taxonomy & unit
us-gaap: USD
Description
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
Summary
Vitro Biopharma, Inc. quarterly Stockholders' Equity Attributable to Parent history and change rate from Q3 2011 to Q2 2025.
  • Vitro Biopharma, Inc. Stockholders' Equity Attributable to Parent for the quarter ending 31 Jul 2025 was -$12.1M, a 65% decline year-over-year.
Stockholders' Equity Attributable to Parent, Quarterly (USD)
Stockholders' Equity Attributable to Parent, YoY Quarterly Change (%)

Vitro Biopharma, Inc. Quarterly Stockholders' Equity Attributable to Parent (USD)

Period Value YoY Chg Change % Date Report Filed
Q2 2025 -$12.1M -$4.76M -65% 31 Jul 2025 10-Q 12 Sep 2025
Q1 2025 -$11.1M -$3.51M -46.4% 30 Apr 2025 10-Q 12 Sep 2025
Q4 2024 -$9.91M -$5.08M -105% 31 Jan 2025 10-Q 12 Sep 2025
Q3 2024 -$9M -$7.91M -725% 31 Oct 2024 10-Q 12 Sep 2025
Q2 2024 -$7.32M -$7.72M -1933% 31 Jul 2024 10-Q 12 Sep 2025
Q1 2024 -$7.56M -$8.44M -954% 30 Apr 2024 10-Q 12 Sep 2025
Q4 2023 -$4.83M -$6.73M -353% 31 Jan 2024 10-Q 12 Sep 2025
Q3 2023 -$1.09M -$3.93M -138% 31 Oct 2023 10-Q 12 Sep 2025
Q2 2023 $400K -$4.48M -91.8% 31 Jul 2023 10-Q 16 Sep 2024
Q1 2023 $885K -$5.46M -86.1% 30 Apr 2023 10-Q 16 Sep 2024
Q4 2022 $1.91M -$1.43M -42.8% 31 Jan 2023 10-Q 16 Sep 2024
Q3 2022 $2.84M -$619K -17.9% 31 Oct 2022 10-K 28 Jan 2025
Q2 2022 $4.88M 31 Jul 2022 10-Q 28 Aug 2023
Q1 2022 $6.35M 30 Apr 2022 10-Q 28 Aug 2023
Q4 2021 $3.34M 31 Jan 2022 10-Q 28 Aug 2023
Q3 2021 $3.45M 31 Oct 2021 10-K 29 Jan 2024
Q3 2015 -$2.38M -$222K -10.3% 31 Oct 2015 10-K 22 Sep 2016
Q2 2015 -$2.32M -$232K -11.1% 31 Jul 2015 10-Q 30 Mar 2016
Q1 2015 -$2.28M -$237K -11.6% 30 Apr 2015 10-Q 22 Jan 2016
Q4 2014 -$2.21M -$220K -11.1% 31 Jan 2015 10-Q 24 Mar 2015
Q3 2014 -$2.16M -$227K -11.7% 31 Oct 2014 10-K 22 Sep 2016
Q2 2014 -$2.09M -$198K -10.5% 31 Jul 2014 10-Q 22 Sep 2014
Q1 2014 -$2.05M -$187K -10% 30 Apr 2014 10-Q 19 Jun 2014
Q4 2013 -$1.99M -$196K -10.9% 31 Jan 2014 10-Q 17 Mar 2014
Q3 2013 -$1.93M -$179K -10.2% 31 Oct 2013 10-K 13 Feb 2015
Q2 2013 -$1.89M -$172K -10% 31 Jul 2013 10-Q 23 Sep 2013
Q1 2013 -$1.86M 30 Apr 2013 10-Q 18 Jun 2013
Q4 2012 -$1.79M 31 Jan 2013 10-Q 21 Mar 2013
Q3 2012 -$1.75M -$188K -12% 31 Oct 2012 10-K 12 Feb 2014
Q2 2012 -$1.72M 31 Jul 2012 10-Q/A 17 Oct 2012
Q3 2011 -$1.57M 31 Oct 2011 10-K 12 Feb 2013
* An asterisk sign (*) next to the value indicates that the value is likely invalid.